Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.
Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, Willing A, Trebst C, Pawlitzki M, Abdelhak A, Grüter T, Leypoldt F, Haas J, Kleiter I, Tumani H, Fechner K, Reindl M, Paul F, Wildemann B. Jarius S, et al. Among authors: pawlitzki m. J Neuroinflammation. 2018 Mar 19;15(1):88. doi: 10.1186/s12974-018-1108-6. J Neuroinflammation. 2018. PMID: 29554927 Free PMC article. Review.
ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports.
Körtvélyessy P, Breu M, Pawlitzki M, Metz I, Heinze HJ, Matzke M, Mawrin C, Rommer P, Kovacs GG, Mitter C, Reindl M, Brück W, Wandinger KP, Lassmann H, Höftberger R, Leypoldt F. Körtvélyessy P, et al. Among authors: pawlitzki m. Neurol Neuroimmunol Neuroinflamm. 2017 Mar 14;4(3):e335. doi: 10.1212/NXI.0000000000000335. eCollection 2017 May. Neurol Neuroimmunol Neuroinflamm. 2017. PMID: 28331892 Free PMC article. No abstract available.
Transient MOG antibody seroconversion associated with immunomodulating therapy.
Pawlitzki M, Campe C, Rolfes L, Heinze HJ, Leypoldt F, Wandinger KP, Reindl M, Wildemann B, Jarius S, Körtvelyessy P. Pawlitzki M, et al. Mult Scler Relat Disord. 2020 Jan;37:101420. doi: 10.1016/j.msard.2019.101420. Epub 2019 Sep 28. Mult Scler Relat Disord. 2020. PMID: 32172994
Pain, depression, and quality of life in adults with MOG-antibody-associated disease.
Asseyer S, Henke E, Trebst C, Hümmert MW, Wildemann B, Jarius S, Ringelstein M, Aktas O, Pawlitzki M, Korsen M, Klotz L, Siebert N, Ruprecht K, Bellmann-Strobl J, Wernecke KD, Häußler V, Havla J, Gahlen A, Gold R, Paul F, Kleiter I, Ayzenberg I; Neuromyelitis Optica Study Group. Asseyer S, et al. Among authors: pawlitzki m. Eur J Neurol. 2021 May;28(5):1645-1658. doi: 10.1111/ene.14729. Epub 2021 Feb 11. Eur J Neurol. 2021. PMID: 33423336
Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.
Pfeuffer S, Ruck T, Pul R, Rolfes L, Korsukewitz C, Pawlitzki M, Wildemann B, Klotz L, Kleinschnitz C, Scalfari A, Wiendl H, Meuth SG. Pfeuffer S, et al. Among authors: pawlitzki m. J Neurol Neurosurg Psychiatry. 2021 Sep;92(9):1007-1013. doi: 10.1136/jnnp-2020-325304. Epub 2021 Mar 12. J Neurol Neurosurg Psychiatry. 2021. PMID: 33712515 Free PMC article.
89 results